

#### External urethral sphincter injections with Basel botulinumtoxin A in patients with neurogenic detrusor sphincter dyssynergia without REHAB spinal cord lesions: a retrospective study


Ralf Anding<sup>1</sup>, Kilian Roethlin<sup>2</sup>, Sandra Moehr<sup>3</sup>, Matthias Walter<sup>1</sup>

<sup>1</sup>Urology, University Hospital Basel, <sup>2</sup>Urology, Kantonsspital Luzern, <sup>3</sup>Neurourology, REHAB Basel, Switzerland

### Introduction

Botulinumtoxin A (BoNT-A) injections into the external urethral sphincter (EUS) is an established therapeutic procedure to reduce bladder outlet obstruction in neurogenic patients with detrusor-sphincter-dyssynergia (DSD) due to spinal cord injury (SCI).

Given the paucity of data in patients with DSD but without SCI, we aimed to assess the efficacy of transperineal electromyography (EMG) directed EUS injections with BoNT-A in a cohort of patients with suprapontine cerebral lesions.



# dyssynergia (DSD)

## **Design and Methods**

Clin	ic for neurorehabilitation and			
para	aplegiology (REHAB) Basel (CH)			
13 men, mean age 31 years [24 – 42 years]				
•	Traumatic brain injury	(n = 6)		
•	Hypoxic encephalopathy	(n = 3)		
•	Stroke	(n = 1)		
•	Cerebral palsy	(n = 1)		
•	Other	(n = 2)		
•	Neurogenic detrusor overactivity	(NDO)		
•	Maximum detrusor pressure (P <sub>de</sub>	<sub>et</sub> max)		
	during voiding of at least 40 cm	H <sub>2</sub> O		
•	DSD			
•	Confirmed by urodynamics (UDS	S)		
2015 – 2021				

Video-Urodynamics before and after Botox<sup>®</sup> > Outcome: Reduction of maximal detrusor pressure (Pdetmax) after Botox® **Reduction of DO Leak Point Pressure** (DOLPP) after Botox<sup>®</sup> Reduction of patients with indwelling caths after Botox® > Statistics: Non-parametric (R, Version 4.0.5 for MacOS) Institutional ethical approval




Fig. 2. Perineal EMG triggered Botox<sup>®</sup> injection under rectal finger guidance (Figures from Ref. 1. and 2.)

Fig. 3. Dantec<sup>™</sup> Clavis<sup>™</sup> device for EMG-guided injections with Bo-ject<sup>®</sup> hypodermic needle electrode

1<sup>st</sup> administration of Botox<sup>®</sup> in the EUS EMG triggered Botox<sup>®</sup> injection

- 100 Units (n = 7)
- 150 Units (n = 6)

## **Results**

 $\succ$  Ethics:

 $\succ$  Therapy:

> Technique:

Urodynamic parameters	Before	After	
Pdetmax [cmH <sub>2</sub> O]	105 ( 85; 113, 44 – 143)	54 (49; 70, 37 – 100)	p=0.006
DOLPP [cmH <sub>2</sub> O]	50 (40; 78.8, 34 – 126)	50 (36.2; 56.8, 30 – 90)	p=0.33
Incontinence volume [mL]	120 (70; 180, 0 – 360)	220 (68; 374, 30 – 572)	p <0.05
Max. Capacity [mL]	190 (120; 275, 60 – 360)	220 (108; 336, 30 – 770)	
Residual urine [mL]	0 (0; 46, 0 – 160)	0 (0; 150, 0 – 323)	

Median (lower quartile; upper quartile, minimum – maximum)

Mode of bladder drainage (before / after)

- > Reflex micturion (n = 6 / n = 13)
- > Indwelling catheter (n = 7 / n = 0)




Fig. 4. Radiographic example of micturition before and after Botox® injection

#### **Conclusions**

Transperineal BoNT-A injections into the external urethral sphincter in male patients with NDO and DSD without underlying SCI is

- ➤ feasible
- > significantly reduced bladder outlet obstruction in this cohort
- > reduced number of patients with indwelling catheters to zero in our cohort

#### **References**

- 1. Shafik A, El-Sibai O. Botulin Toxin in the Treatment of Nonrelaxing Puborectalis Syndrome. Dig Surg 1998;15:347-351
- 2. De Ridder D, Rehder P. The AdVance<sup>®</sup> Male Sling: Anatomic Features in Relation to Mode of Action. Eur Urol Suppl 2011;10:383-389